SHINIL PHARMACEUTICAL CO., LTD.

012790KOSDAQPharmaceuticals

SHINIL PHARMACEUTICAL CO., LTD. (012790, KOSDAQ) reported KRW 81bn revenue in 2025.

Reported financials

Figures are as filed with the Korean regulator, in billions of won (KRW bn). We do not convert to dollars — an exchange rate would be a number we made up, not one the company reported.

YearRevenueOperating profitNet profitAssetsEquityBasis
2023891414152135Separate
2024891514166147Separate
20258178169152Separate

Ratios, year by year

Each ratio is computed inside its own year. A dash means the input was missing or the denominator was zero — not that the value is zero.

YearOperating marginNet marginEquity / assetsReturn on equity
202315.7%15.3%88.5%10.1%
202417%16%88.3%9.8%
20259.2%9.3%89.9%4.9%

Revenue moved -9.6% between 2023 and 2025.

These are arithmetic, not judgements. We do not say whether a margin is good or bad, and we do not rank companies against each other.

Market size

Market capitalisationKRW 73bn
Close priceKRW 6,050
Listed shares11,986,415
Price as of20260909

Market capitalisation is what buyers are betting the company is worth. It is not something the company produced, so we never present it as output or productivity.

Workforce — a side measure, not the main one

Employees (2025)413
Women163 (39.5%)
Average tenure6.9 years
Annual pay, menKRW 53,753,000
Annual pay, womenKRW 43,879,000
Pay ratio, women to men81.6%

Other companies in Pharmaceuticals

181 listed companies file under this classification. Showing 12.

See the whole Pharmaceuticals list →